Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1565]

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first...

Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC ( Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia )

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell...

Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )

A new era of early cancer detection with blood test may change cancer screening...

Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA

A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Lenvatinib remains standard of care for first-line therapy in advanced...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC...

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

Lasofoxifene shows promise for women with ESR1-mutated mBC

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

Scientists discover mechanism of action and an actionable inflammatory axis for...

Prof Charles Swanton - The Francis Crick Institute, London, UK

Scientists discover mechanism of action and an actionable inflammatory axis for air pollution induced NSCLC ( Prof Charles Swanton - The Francis Crick Institute, London, UK )

Bladder cancer: Current state and future directions in treatment

Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case...

Bladder cancer: Current state and future directions in treatment ( Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case Western Reserve University, Cleveland, USA )

Optimum treatment algorithm in management of advanced prostate cancer

Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case...

Optimum treatment algorithm in management of advanced prostate cancer ( Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case Western Reserve University, Cleveland, USA )

Working to improve global cancer care access in low middle-income countries

Dr Julie Gralow, Prof Eduardo Cazap

Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )

More from ecancer